ArticleCancers2026
FibroidX: Vision Transformer-Powered Prognosis and Recurrence Prediction for Uterine Fibroids Using Ultrasound Images.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesOne of the common gynecological issues that can have a major effect on women's reproductive health and quality of life is uterine fibroids (UFs). For personalized treatment planning and a reduction in long-term consequences, early fibroid prognosis and recurrence prediction are essential. In this context, prognosis refers to anticipated symptom progression and treatment response, while recurrence prediction estimates the likelihood of regrowth after interventions such as myomectomy, uterine artery embolization (UAE), or new fibroid formation during follow-up. Conventional techniques for predicting the prognosis and recurrence of UFs depend on imaging, clinical evaluations, and statistical models; nevertheless, they frequently have limited accuracy and are subjective.
methodsTherefore, we introduce FibroidX, which utilizes vision transformers and self-attention processes to improve forecast accuracy, automate feature extraction, and offer customized risk evaluations to overcome these obstacles. Prognosis encompasses overall disease progression, symptom severity, and response to therapy, whereas recurrence prediction focuses on post-treatment regrowth or new fibroid formation.
resultsThe dataset comprises 1990 ultrasound images split into training-test sets (80-20). With an accuracy of 98.4%, the suggested model outperformed baseline models like Model A (92.3%) and Model B (94.1%), exhibiting exceptional performance. A significant percentage of accurately anticipated cases was ensured by the precision and recall values, which were 97.8% and 96.9%, respectively. The model's balanced precision-recall trade-off is highlighted by its F1-score of 97.3%, and its exceptional class distinction is confirmed by its AUC-ROC score of 0.99.
conclusionsThe model was suitable for real-time applications, with an average inference time of 0.02 s per sample. The proposed method showed its effectiveness and reliability in prediction tasks. It achieved a 15% increase in accuracy and a 12% reduction in the false positive rate compared to traditional machine learning techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.